SEC Form 4 · accession 0001209191-18-057261
ALDER BIOPHARMACEUTICALS INC · ALDR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A Latham
Officer — Chief Scientific Officer
Period of report
Nov 1, 2018
Accepted (ET)
Nov 5, 2018 · 5:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001423824
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 1, 2018 | M | 6,821 | $6.765 | A | 250,514 | D | |
| Common StockF1 | Nov 1, 2018 | M | 18,181 | $10.00 | A | 268,695 | D | |
| Common StockF2,F3 | Nov 1, 2018 | S | 23,683 | $13.4028 | D | 245,012 | D | |
| Common StockF2,F4 | Nov 1, 2018 | S | 1,319 | $13.7758 | D | 243,693 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $6.765 | Nov 1, 2018 | M | 6,821 | D | — | Feb 10, 2024 | Common Stock | 6,821 | 0 | D |
| Stock Option (Right to Buy)F5 | $10.00 | Nov 1, 2018 | M | 18,181 | D | — | May 6, 2024 | Common Stock | 18,181 | 0 | D |
Explanation of responses
- F1The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.77 to $13.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.77 to $13.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
- F5The shares subject to this stock option are fully vested.